Ulinastatin, UTI

Specification

• Cat#: THP-0217
• Product Name: Ulinastatin, UTI
• Description: Ulinastatin, as an urinary trypsin inhibitor (UTI), is a glycoprotein that is isolated from healthy human urine or synthetically produced and has molecular weight of 25 - 40kDa. Highly purified ulinastatin has been clinically used for the treatment of acute pancreatitis, chronic pancreatitis, Stevens–Johnson syndrome, burns, septic shock, and toxic epidermal necrolysis (TEN).
• Source: Human urine
• Introduction: As a proteinase inhibitor, it inhibits the activity of trypsin, chymotrypsin, lactate, lipase, hyaluronidase and other pancreatic enzymes. UTI is an effective for acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks. UTI is has strong inhibition effect to various protease, sugar and fat hydrolase.
• Purity: >98.0% as determined by the following methods: (a) RP-HPLC analysis (b) Anion-exchange FPLC (c) Reducing and non-reducing SDS-PAGE Silver Stained gel analysis
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Biological Activity: HuUTI has an activity of 1000 IU/mg
• Reconstitution: It is recommended that the lyophilized HuUTI be reconstituted in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
• Dimers: < 1% as determined by silver-stained SDS-PAGE gel analysis
• Application: UTI is an effective for acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks.

Pharmaceutical Information

• Pharmaceutical Application: Ulinastatin